Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT
© 2020 by The American Society of Hematology..
Human herpesvirus 6B (HHV-6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT). There are no randomized studies of antiviral treatments to prevent HHV-6B reactivation. Brincidofovir has high in vitro activity against HHV-6B and other DNA viruses, but its in vivo activity for HHV-6B has not been demonstrated. We performed a post hoc analysis of a randomized controlled trial of twice-weekly oral brincidofovir for cytomegalovirus prophylaxis after allogeneic HCT to study the effect of brincidofovir on HHV-6B reactivation. We included patients randomized within 2 weeks of HCT and who received at least 6 consecutive doses of study drug after randomization. We tested plasma for HHV-6B through week 6 post-HCT. The cohort consisted of 92 patients receiving brincidofovir and 61 receiving placebo. The cumulative incidence of HHV-6B plasma detection through day 42 post-HCT was significantly lower among patients receiving brincidofovir (14.2%) compared with placebo (32.4%; log-rank, 0.019). In an adjusted Cox model, brincidofovir exposure remained associated with a lower hazard for HHV-6B plasma detection (hazard ratio, 0.40; 95% confidence interval, 0.20-0.80). In conclusion, brincidofovir prophylaxis reduced HHV-6B reactivation after allogeneic HCT in a post hoc analysis of a randomized controlled trial. These data support the study of intravenous brincidofovir for HHV-6B prophylaxis.
| Errataetall: |
CommentIn: Blood. 2020 Apr 23;135(17):1413-1414. - PMID 32324868 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
Blood - 135(2020), 17 vom: 23. Apr., Seite 1447-1451 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hill, Joshua A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6794O900AX |
|---|
| Anmerkungen: |
Date Completed 31.12.2020 Date Revised 30.04.2021 published: Print CommentIn: Blood. 2020 Apr 23;135(17):1413-1414. - PMID 32324868 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2019004315 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306705907 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306705907 | ||
| 003 | DE-627 | ||
| 005 | 20231225123948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2019004315 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306705907 | ||
| 035 | |a (NLM)32076716 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hill, Joshua A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.12.2020 | ||
| 500 | |a Date Revised 30.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood. 2020 Apr 23;135(17):1413-1414. - PMID 32324868 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 by The American Society of Hematology. | ||
| 520 | |a Human herpesvirus 6B (HHV-6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT). There are no randomized studies of antiviral treatments to prevent HHV-6B reactivation. Brincidofovir has high in vitro activity against HHV-6B and other DNA viruses, but its in vivo activity for HHV-6B has not been demonstrated. We performed a post hoc analysis of a randomized controlled trial of twice-weekly oral brincidofovir for cytomegalovirus prophylaxis after allogeneic HCT to study the effect of brincidofovir on HHV-6B reactivation. We included patients randomized within 2 weeks of HCT and who received at least 6 consecutive doses of study drug after randomization. We tested plasma for HHV-6B through week 6 post-HCT. The cohort consisted of 92 patients receiving brincidofovir and 61 receiving placebo. The cumulative incidence of HHV-6B plasma detection through day 42 post-HCT was significantly lower among patients receiving brincidofovir (14.2%) compared with placebo (32.4%; log-rank, 0.019). In an adjusted Cox model, brincidofovir exposure remained associated with a lower hazard for HHV-6B plasma detection (hazard ratio, 0.40; 95% confidence interval, 0.20-0.80). In conclusion, brincidofovir prophylaxis reduced HHV-6B reactivation after allogeneic HCT in a post hoc analysis of a randomized controlled trial. These data support the study of intravenous brincidofovir for HHV-6B prophylaxis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 650 | 7 | |a Organophosphonates |2 NLM | |
| 650 | 7 | |a brincidofovir |2 NLM | |
| 650 | 7 | |a 6794O900AX |2 NLM | |
| 650 | 7 | |a Cytosine |2 NLM | |
| 650 | 7 | |a 8J337D1HZY |2 NLM | |
| 700 | 1 | |a Nichols, W Garrett |e verfasserin |4 aut | |
| 700 | 1 | |a Marty, Francisco M |e verfasserin |4 aut | |
| 700 | 1 | |a Papanicolaou, Genovefa A |e verfasserin |4 aut | |
| 700 | 1 | |a Brundage, Thomas M |e verfasserin |4 aut | |
| 700 | 1 | |a Lanier, Randall |e verfasserin |4 aut | |
| 700 | 1 | |a Zerr, Danielle M |e verfasserin |4 aut | |
| 700 | 1 | |a Boeckh, Michael J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 135(2020), 17 vom: 23. Apr., Seite 1447-1451 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2020 |g number:17 |g day:23 |g month:04 |g pages:1447-1451 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2019004315 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2020 |e 17 |b 23 |c 04 |h 1447-1451 | ||